Assessing sample representativeness in randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network

被引:49
|
作者
Susukida, Ryoko [1 ]
Crum, Rosa M. [1 ,2 ,3 ]
Stuart, Elizabeth A. [1 ]
Ebnesajjad, Cyrus [1 ]
Mojtabai, Ramin [1 ,3 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 North Broadway Room 897, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
关键词
Clinical trials; sample representativeness; substance use disorders; MOTIVATIONAL ENHANCEMENT THERAPY; BUPRENORPHINE-NALOXONE; SOCIOECONOMIC-STATUS; SUBSTANCE-ABUSE; GENERALIZABILITY; DEPENDENCE; INCENTIVES; PREDICTORS; EDUCATION; SELECTION;
D O I
10.1111/add.13327
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To compare the characteristics of individuals participating in randomized controlled trials (RCTs) of treatments of substance use disorder (SUD) with individuals receiving treatment in usual care settings, and to provide a summary quantitative measure of differences between characteristics of these two groups of individuals using propensity score methods. Design Analyses using data from RCT samples from the National Institute of Drug Abuse Clinical Trials Network (CTN) and target populations of patients drawn from the Treatment Episodes Data Set-Admissions (TEDS-A). Settings Multiple clinical trial sites and nation-wide usual SUD treatment settings in the United States. Participants A total of 3592 individuals from 10 CTN samples and 1 602 226 individuals selected from TEDS-A between 2001 and 2009. Measurements The propensity scores for enrolling in the RCTs were computed based on the following nine observable characteristics: sex, race/ethnicity, age, education, employment status, marital status, admission to treatment through criminal justice, intravenous drug use and the number of prior treatments. Findings The proportion of those with >= 12 years of education and the proportion of those who had full-time jobs were significantly higher among RCT samples than among target populations (in seven and nine trials, respectively, at P < 0.001). The pooled difference in the mean propensity scores between the RCTs and the target population was 1.54 standard deviations and was statistically significant at P < 0.001. Conclusions In the United States, individuals recruited into randomized controlled trials of substance use disorder treatments appear to be very different from individuals receiving treatment in usual care settings. Notably, RCT participants tend to have more years of education and a greater likelihood of full-time work compared with people receiving care in usual care settings.
引用
收藏
页码:1226 / 1234
页数:9
相关论文
共 50 条
  • [31] Assessing the Population Representativeness of Colorectal Cancer Treatment Clinical Trials
    He, Zhe
    Chen, Zhiwei
    George, Thomas J., Jr.
    Lipori, Gloria
    Jiang, Bian
    2016 38TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2016, : 2970 - 2973
  • [32] A National Cancer Clinical Trials Network: Recommendations From the Institute of Medicine
    Nass, Sharyl J.
    Balogh, Erin
    Mendelsohn, John
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (05) : 382 - 391
  • [33] Controlled randomized clinical trials
    Jaillon, Patrice
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2007, 191 (4-5): : 739 - 756
  • [34] The National Cancer Institute's Experimental Therapeutics Clinical Trials Network
    Ivy, S. Percy
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (03) : 144 - 146
  • [35] Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies
    Unger, Joseph M.
    Hershman, Dawn L.
    Osarogiagbon, Raymond U.
    Gothwal, Anirudh
    Anand, Seerat
    Dasari, Arvind
    Overman, Michael
    Loree, Jonathan M.
    Raghav, Kanwal
    JNCI CANCER SPECTRUM, 2020, 4 (04)
  • [36] Impact of Behavioral Drug Abuse Treatment on Sexual Risk Behaviors: An Integrative Data Analysis of Eight Trials Conducted Within the National Drug Abuse Treatment Clinical Trials Network
    Jennifer L. Brown
    Michael D. Eriksen
    Nicole K. Gause
    Gene H. Brody
    Jessica M. Sales
    Prevention Science, 2018, 19 : 761 - 771
  • [37] Impact of Behavioral Drug Abuse Treatment on Sexual Risk Behaviors: An Integrative Data Analysis of Eight Trials Conducted Within the National Drug Abuse Treatment Clinical Trials Network
    Brown, Jennifer L.
    Eriksen, Michael D.
    Gause, Nicole K.
    Brody, Gene H.
    Sales, Jessica M.
    PREVENTION SCIENCE, 2018, 19 (06) : 761 - 771
  • [38] THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK: BRIDGING THE GAP BETWEEN RESEARCH AND PRACTICE TO IMPROVE DRUG ABUSE TREATMENT.
    Horigian, V
    INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2012, 19 : S123 - S124
  • [39] A Systematic Scoping Review of Research on Black Participants in the National Drug Abuse Treatment Clinical Trials Network
    Montgomery, LaTrice
    Burlew, Ann Kathleen
    Haeny, Angela M.
    Jones, Chizara A.
    PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2020, 34 (01) : 117 - 127
  • [40] Maximizing Effectiveness Trials in PTSD and SUD Through Secondary Analysis: Benefits and Limitations Using the National Institute on Drug Abuse Clinical Trials Network "Women and Trauma" Study as a Case Example
    Hien, Denise A.
    Campbell, Aimee N. C.
    Ruglass, Lesia M.
    Saavedra, Lissette
    Mathews, Abigail G.
    Kiriakos, Grace
    Morgan-Lopez, Antonio
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2015, 56 : 23 - 33